Technology ID
E-157-2011

CNS Therapeutics That Target Neuronal Ceroid-Lipofuscinoses and Thioesterase Deficiency Disorders

Linked ID
NCI-E-157-2011
Inventors
Anil Mukherjee (NICHD)
Chinmoy Sarkar (NICHD)
Zhongjian Zhang (NICHD)
Lead Inventors
Anil Mukherjee (NICHD)
Co-Inventors
Chinmoy Sarkar (NICHD)
Zhongjian Zhang (NICHD)
Development Stages
Pre-clinical (in vivo)
Development Status
Pre-clinical (in vivo)
Applications
Therapeutics
ICs
NICHD
Commercial Applications
  • Small molecule therapeutic for neuronal ceroid-lipfuscinoese
  • Small molecule to treat or prevent thioesterase deficiency disorders.
Clinically known as Neuronal Ceroid-Lipofuscinoses(NCL), Batten disease, is a rare neuron killing disease and one of the lysosomal storage disorders (LSDs). It is associated with a mutation or lack of palmitoyl-protein thioesterase-1 (PPT1) gene. It manifests very early in a child's life causing absence of brain activity as early as 4 years of age.Dr. Mukherjeof NICHD has discovered and developed N-t-BuHA, a chemical derivative of hydroxylamine that mimics the action of PPT1 enzyme. Compared to hydroxylamine, N-t-BuHA has been shown to be non-toxic in mice expressing batten disease. In addition, NtBuHA exhibited potent antioxidant property and extended the life of the diseased mice. NtBuHA has shown promising therapeutic potential to treat NCL-LSDs.
Competitive Advantages
  • First of its kind to treat INCL and other LSD
  • Non-toxic dertivative therapeutic against thioesterase deficiency disorders

Request More Info

Licensing Contact